Oncolytics Biotech

Biotechnology
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

$87.1M

Market Cap • 9/25/2026

1998

(28 years)

Founded

2001

(25 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

87,1M

EV

83,5M

EV/Revenue

0

EV/EBITDA

-2,7

EV/EBIT

-2,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-18,8%

Total Yield

-18,8%

Payout

0%

Retained Earnings

-448,2M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

20,8%

Capex/OCF

0%

SBC/OCF

—

% PPE

7,8%

% Goodwill

0%

ROE

3571,6%

ROIC

—

Growth

CAGR Op. Income 5Y

7,5%

CAGR Net Income 5Y

5,2%

CAGR EPS 5Y

-6,7%

CAGR OCF 5Y

1,6%

Leverage

N.D./EBITDA

0,1

Debt/Equity

0%

Current Ratio

1,4

Quick Ratio

1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium